Download PDF

1. Company Snapshot

1.a. Company Description

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas.The company acquires, markets, and distributes consumer healthcare and prescription medicine products.It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products.


The company also offers medical devices, food supplements, and cosmetics.Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names.The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.

Show Full description

1.b. Last Insights on APH

Alliance Pharma's business condition is evolving with potential value opportunities. As highlighted on January 28, 2025, the company is one of the UK penny stocks to consider, indicating its potential for growth. Recent Form 8.3 filings from various companies, including Hargreaves Lansdown and Direct Line Insurance Group, suggest increased investor interest. No recent earnings release or significant new product announcements have been made, but the company's presence in the UK market may attract investors seeking value in smaller companies.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Alliance Pharmaceuticals Ltd Partners with TrueMed to Combat Sophisticated Counterfeits with AI-Powered Authentication

Jul -15

Source:

Card image cap

Form 8.3 - Direct Line Insurance Group plc

Mar -19

Source:

Card image cap

Form 8.3 - Assura PLC

Mar -12

Source:

Card image cap

Alliance Pharma agrees to £362m acquisition by DBAY

Mar -10

Source:

Card image cap

Form 8.3 - Aviva plc

Mar -07

Source:

Card image cap

Form 8.3 - Direct Line Insurance Group plc

Mar -06

Source:

Card image cap

Form 8.3 - Direct Line Insurance Group plc

Mar -04

Source:

Card image cap

Form 8.3 - Aviva plc

Mar -03

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (3.78%)

6. Segments

Consumer Healthcare

Expected Growth: 3.5%

Alliance Pharma's Consumer Healthcare segment growth of 3.5% is driven by increasing demand for self-care products, an aging population, and rising healthcare expenditure. Additionally, the company's strategic acquisitions and partnerships have expanded its product portfolio and geographic reach, contributing to growth. Furthermore, the segment's focus on niche and specialty products has helped to mitigate competition and maintain pricing power.

Prescription Medicines

Expected Growth: 4.5%

Alliance Pharma plc's Prescription Medicines segment growth of 4.5% is driven by increasing demand for specialty pharmaceuticals, strategic product acquisitions, and expansion into emerging markets. Additionally, the company's focus on niche therapeutic areas, such as dermatology and oncology, has contributed to its growth momentum.

7. Detailed Products

Kelo-cote

A topical silicone gel for the management and prevention of scars

MacuShield

A dietary supplement containing meso-zeaxanthin, lutein, and zeaxanthin

Xonvea

A prescription-only medication for the treatment of nausea and vomiting in pregnancy

Nizoral

A medicated shampoo for the treatment of fungal infections of the scalp

Hydromol

A range of emollients for the treatment of dry skin conditions

8. Alliance Pharma plc's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Alliance Pharma plc is moderate, as there are alternative products available in the market, but they are not significantly cheaper or better than Alliance Pharma's products.

Bargaining Power Of Customers

The bargaining power of customers for Alliance Pharma plc is low, as the company has a diverse customer base and no single customer accounts for a significant portion of its revenue.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Alliance Pharma plc is moderate, as the company relies on a few key suppliers for its raw materials, but it also has some bargaining power due to its size and reputation.

Threat Of New Entrants

The threat of new entrants for Alliance Pharma plc is high, as the pharmaceutical industry is highly competitive and new companies can easily enter the market with innovative products.

Intensity Of Rivalry

The intensity of rivalry for Alliance Pharma plc is high, as the company operates in a highly competitive industry with many established players, and it needs to constantly innovate and differentiate itself to stay ahead.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 31.84%
Debt Cost 6.98%
Equity Weight 68.16%
Equity Cost 6.98%
WACC 6.98%
Leverage 46.71%

11. Quality Control: Alliance Pharma plc passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Kamada

A-Score: 5.4/10

Value: 4.9

Growth: 5.7

Quality: 6.8

Yield: 3.1

Momentum: 9.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Pharmanutra

A-Score: 4.2/10

Value: 1.8

Growth: 6.6

Quality: 8.1

Yield: 3.1

Momentum: 0.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Alliance Pharma

A-Score: 4.0/10

Value: 5.0

Growth: 2.9

Quality: 3.6

Yield: 1.9

Momentum: 9.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
InterCure

A-Score: 3.1/10

Value: 9.0

Growth: 2.3

Quality: 2.9

Yield: 0.0

Momentum: 3.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Probi

A-Score: 2.9/10

Value: 0.6

Growth: 3.0

Quality: 4.2

Yield: 0.0

Momentum: 8.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Benchmark

A-Score: 2.7/10

Value: 6.6

Growth: 2.3

Quality: 5.2

Yield: 0.0

Momentum: 0.0

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.65$

Current Price

0.65$

Potential

-0.00%

Expected Cash-Flows